WHO decision clears path for GSK’s Mosquirix malaria vaccine

The World Health Organization (WHO) has awarded prequalification to GSK’s (LSE/NYSE:GSK) Mosquirix.

The move marks the first time that a malaria vaccine has won prequalification.

The WHO decision regarding the Mosquirix malaria vaccine is a prerequisite for United Nations (UN) agencies like UNICEF to procure the vaccine in regions with moderate to high P. falciparum malaria transmission.

Malaria was associated with 409,000 deaths in 2019, according to WHO.

GSK shares fell 1.19% in afternoon trading to $31.47.

The Mosquirix malaria vaccine is also referred to as RTS and S/AS01.

Mosquirix has a long developmental history. GSK began developing the vaccine, then known as RTS,S, in 1987.

In 2001, GSK and PATH’s Malaria Vaccine Initiative entered into a public-private partnership to develop the vaccine for infants and young children in malaria-prone countries.

To win the WHO prequalification, GSK shared detailed c…

Read more
  • 0

TIME recognizes Abbott among this year’s 100 best inventions

The BinaxNow COVID-19 Ag Card [Image courtesy of Abbott]

Abbott (NYSE:ABT) was among a series of medtech companies to receive recognition from TIME in its list of 2021’s best inventions.

The list of the year’s top inventions included Abbott’s innovations twice, with a nod to its NeuroSphere Virtual Clinic and its at-home COVID-19 testing offerings.

NeuroSphere Virtual Clinic allows physicians to speak to patients over a video app and to remotely adjust Abbott’s implanted neuromodulation devices. The platform won FDA approval in March and Time reported that the company plans to expand availability of NeuroSphere Virtual Clinic soon.

Abbott’s BinaxNOW was one of several at-home, over-the-counter COVID-19 tests to receive a mention from Time as the news organization recognized the tests for aiding in efforts to prevent the spread of the virus.

In a post on LinkedI…

Read more
  • 0